

application addresses technologies which encompass the broad category of T-cell receptor and chimeric T-cell technologies. As such, it is likely that the technologies will have numerous applications in the field of immunotherapy and will potentially be licensable to multiple applicants for a variety of novel therapeutic approaches. (portfolio: Gene-Based Therapies—Therapeutics, delivery systems; Cancer—Therapeutics, immunomodulators and immunostimulants; Cancer—Therapeutics, vaccines; Cancer—Therapeutics, gene therapy, genes)

Process for Producing Monoclonal Antibodies Reactive With Human Breast Cancer

J Schlom, D Colcher, M Nuti, PM Hand, FC Austin (NCI)
Serial No. 06/330,959 filed 15 Dec 81
U.S. Patent No. 4,522,918 issued 11 June 85
Licensing Contact: Joseph Contrera, M.S., J.D., 301/496-7056 ext 244

Breast cancer is the second leading cause of cancer death among women, having only recently been surpassed by lung cancer. The incidence rate has remained somewhat steady, and is currently about 108 per 100,000. This invention describes a process to produce antibodies from hybridoma cultures for the detection, prognosis, and treatment of human breast cancer. These eleven antibodies are activated only by tumor cells from human mammary cells and not by apparently normal human tissues. The isotopes of ten and the antibodies are IgG of various subclasses, and one is IgM. The antibodies may be useful in five major areas in the management of human breast cancer: (1) The diagnosis of primary and metastatic breast tumor lesions by assay of human body fluids; (2) the in-situ detection, via gamma scanning, of primary or metastatic breast tumor lesions; (3) the treatment of primary or metastatic breast cancer using one or a combination of the antibodies either alone or coupled with toxic drugs, compounds, or radioactive isotopes; (4) use of the antibodies in the staining of populations of human cells in tissue sections from tumor lesions to indicate the degree of malignancy of the cell populations; and (5) the detection of micro-lesions containing only a few cells that could not be detected by conventional staining techniques. A patent for this invention has been issued by the U.S. Patent and Trademark Office. (portfolio: Cancer—Diagnostics, in vitro, MAb based; Cancer—Research Materials, MAb based)

Dated: December 23, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-332 Filed 1-7-97; 8:45 am]
BILLING CODE 4140-01-M

National Institute of Allergy and Infectious Diseases; Notice of Meeting: Microbiology and Infectious Diseases Research Committee

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Microbiology and Infectious Diseases Research Committee, National Institute of Allergy and Infectious Diseases, on February 12-14, 1997 at the Belmont Conference Center, Manor House Conference Room, 6555 Belmont Woods Road, Elkridge, Maryland.

The meeting will be open to the public from 9 a.m. to 10 a.m. on February 12, to discuss administrative details relating to committee business and for program review. Attendance by the public will be limited to space available. In accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and section 10(d) of Public Law 92-463, the meeting will be closed to the public for the review, discussion, and evaluation of individual grant applications and contract proposals from 10 a.m. until recess on February 12, from 9 a.m. until recess on February 13, and from 9 a.m. until adjournment on February 14. These applications, proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Ms. Claudia Goad, Committee Management Officer, National Institute of Allergy and Infectious Diseases, Solar Building, Room 3C26, National Institutes of Health, Bethesda, Maryland, 301-496-7601, will provide a summary of the meeting and a roster of committee members upon request. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Goad in advance of the meeting.

Dr. Gary Madonna, Scientific Review Administrator, Microbiology and Infectious Diseases Research Committee, NIAID, NIH, Solar Building, Room 4C21, Rockville, Maryland 20892,

telephone 301-496-3528, will provide substantive program information.

(Catalog of Federal Domestic Assistance Program No. 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health)

Dated: December 30, 1996.
Paula N. Hayes,
Acting Committee Management Officer, NIH.
[FR Doc. 97-321 Filed 1-7-97; 8:45 am]
BILLING CODE 4140-01-M

National Institute of Child Health and Human Development; Notice of Meeting of the National Advisory Child Health and Human Development Council

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the National Advisory Child Health and Human Development Council on January 27-28, 1997. The meeting will be held in Building 31, Conference Room 10, National Institutes of Health, Bethesda, Maryland. The meeting of the Subcommittee on Planning will be open on January 27. The Subcommittee meeting will be held in Building 31, Room 2A03, from 8:00 a.m. to 9:30 a.m. to discuss program plans and the agenda for the next Council meeting. Attendance by the public will be limited to space available.

The Council meeting will be open to the public on January 27 from 10:00 a.m. until 5:30 p.m. The agenda includes a report by the Director, NICHD, a report by the Mental Retardation and Developmental Disabilities Branch, an update on the Inclusion of Children in Clinical Research, and other business of the Council. The meeting will be open on January 28 upon completion of applications at approximately 1:00 p.m. to adjournment if any policy issues are raised which need further discussion.

In accordance with the provisions set forth in sections 552b(c)(4), and 552b(c)(6), Title 5, United States Code and section 10(d) of Public Law 92-463, the meeting of the full Council will be closed to the public on January 28 from 8:00 a.m. to approximately 1:00 p.m. for the review, discussion, and evaluation of individual grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Ms. Mary Plummer, Executive Secretary, NACHHD, 6100 Executive